Tema ETFs introduced the DICE ETF on September 9, 2026, providing retail investors direct exposure to prediction market platforms Kalshi and Polymarket, which make up about 15% of the fund's assets via private company stakes. This ETF, trading on the Cboe exchange, includes major holdings like Galaxy Digital, Robinhood, Coinbase, and Intercontinental Exchange, offering a new way to invest in the growing event-contract industry. Prediction markets are expected to grow significantly, with trading volumes potentially reaching $1 trillion by 2030, highlighting the sector's expanding influence. Tema previously included Kalshi in another ETF, signaling confidence in the prediction market sector's future.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
